Report
Description
Report Description
Bone resorption and bone formation takes place continuously in the body and is a
balanced process, but when there is imbalance in this process the bones get dissolved by
the osteoclasts and start losing calcium. This eventually leads to osteoporosis and other
conditions like hypercalcemia as the calcium mixed in the blood. Bisphosphonates
prevent bone damage and are used for bone strengthening and hardening.
Bisphosphonates are group of drugs having high affinity for the bone tissue and are
widely used for treatment of bone related diseases like osteoporosis, myeloma and bone
metastasis. With the rising incidence rate of myeloma and geriatric population the
Bisphosphonates market is expected to show healthy growth during the forecast period.
The Bisphosphonates market is mainly driven by the incidence and prevalence rate of
bone diseases. The expansion in geriatric population is the major driver for the
bisphosphonates market. Ageing people start losing bone density and may suffer from
fractures therefore bisphosphonate treatment becomes necessary for such patients.
According to the U.S. Department of Health and Human Services, 2013 survey, nearly
14.1% of the U.S. population was aged above 65 years and is increasing rapidly. Another
significant factor favorable for the growth of bisphosphonates market is the escalation in
the number of women in the post-menopausal stage, who suffer from the weakening
bones. The total number of women attaining menopause is estimated to cross 1 bn. by
2025, according to the International Menopause Society the number of menopausal
women is higher in the developing. Incidence rate of cancers like myeloma which cause
loss of bone density. Bisphosphonates are also used for therapy in the patients suffering
from breast cancer and prostate cancer.